Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13409754 | 0.89 | KMT2A (0.45) | MEN1KMT2ATSHRCYP3A4LTA4H | |
| SCHEMBL13409825 | 0.89 | MEN1 (0.44) | MEN1KMT2ATSHRKDM4ECYP3A4 | |
| SCHEMBL13410000 | 0.85 | MEN1 (0.47) | MEN1KMT2ATSHRCYP3A4LTA4H | |
| SCHEMBL13391996 | 0.84 | ATM (0.41) | MEN1KMT2ATSHRACKR3KDM4E | |
| SCHEMBL14078057 | 0.84 | ATM (0.41) | MEN1KMT2ATSHRACKR3KDM4E | |
| SCHEMBL8416759 | 0.83 | MEN1 (0.49) | MEN1KMT2ATSHRL3MBTL1CYP3A4 | |
| SCHEMBL13409997 | 0.82 | MEN1 (0.46) | MEN1KMT2ATSHRCYP3A4 | |
| SCHEMBL13409985 | 0.82 | L3MBTL1 (0.51) | MEN1KMT2ATSHRACKR3L3MBTL1 | |
| SCHEMBL13409979 | 0.82 | KMT2A (0.55) | MEN1KMT2ATSHRKDM4ENPSR1 | |
| SCHEMBL13409748 | 0.81 | CYP3A4 (0.46) | MEN1KMT2ATSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION SECHERING-PLOUGH CORPORATION (US) | 2010-04-15 | — | — | US | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | GPR119, ATF4, GID4 | MEN1 4556/4885KMT2A 3430/4885TSHR 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.